TABLE 3.

Ongoing clinical trials of adjuvant therapy with ICIs for earlier-stage NSCLC.

Clinical trial	Phase	Stage	Intervention used	Estimated sample size	Primary endpoints
ANVIL (NCT02595944)	III	IB–IIIA	Nivolumab vs. observation with or without adjuvant chemotherapy	903	OS, DFS
PEARLS/Keynote-091 (NCT02504372)	III	IB–IIIA	Pembrolizumab vs. placebo with or without adjuvant chemotherapy	1,380	DFS
IMpower010 (NCT02486718)	III	IB–IIIA	Atezolizumab + chemotherapy vs. best supportive care + chemotherapy	1,280	DFS
BR31 (NCT02273375)	III	IB–IIIB	Durvalumab vs. placebo with or without adjuvant chemotherapy	1,100	DFS in PD-L1-positive patients and in all randomized patients

NSCLC, non-small cell lung cancer; ICIs, immune checkpoint inhibitors; OS, overall survival; DFS, disease-free survival; PD-L1, programmed cell death-ligand 1.